Retinal crystalline deposits in a patient who received chemotherapy and radiotherapy for nasopharyngeal carcinoma and subsequent anti-VEGF treatment for the bilateral radiation maculopathy

oc000090 10.3205/oc000090 urn:nbn:de:0183-oc0000904 Case Report Retinal crystalline deposits in a patient who received chemotherapy and radiotherapy for nasopharyngeal carcinoma and subsequent anti-VEGF treatment for the bilateral radiation maculopathy Parlak Parlak Melih M

Ulm University Medical School, Department of Ophthalmology, Ulm, Germany

author Erden Erden Burcin B

Dokuz Eylul University Medical School, Ophthalmology Department, Izmir, Turkey

author Saatci Saatci Ali Osman AO Prof. Dr.

Mustafa Kemal Sahil Bulvarı, No: 73, A Blok D: 9, 35320 Narlıdere/Izmir, TurkeyDokuz Eylul University Medical School, Ophthalmology Department, Izmir, Turkey

osman.saatci@yahoo.com author German Medical Science GMS Publishing House

Düsseldorf

610 cisplatin crystal epirubicin neurodegeneration radiation maculopathy 2019020620190220 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). 2193-1496 9 GMS Ophthalmology Cases GMS Ophthalmol Cases 01 20190220DOI format has been corrected. We report the occurrence of intraretinal crystalline deposits in a patient who received several anti-VEGF injections and one session of focal laser treatment for the treatment of radiation retinopathy during the treatment process. She had received three cycles of epirubicin and cisplatin together with radiation therapy seven years prior to detection of the maculopathy. The multimodal imaging features and the possible cause of the retinal crystalline deposits are discussed. IntroductionRadiation maculopathy (RM) is a sight-threatening consequence of radiotherapy in the management of ocular malignancies or other head tumors. It develops as a slowly progressive retinal microangiopathy and it is histopathologically characterized by vascular remodelling, chorioretinal inflammation, and neurodegeneration , , . Main clinical features are retinal hemorrhages, microaneurysms, telangiectasia, macular edema, and exudation. The incidence depends mainly on the radiation dose as well as the tumor location and radiation sens</PlainText></TextGroup>it<TextGroup><PlainText>izers</PlainText></TextGroup> <TextLink reference="4"></TextLink>, <TextLink reference="5"></TextLink>. We report an unusual RM case with retinal crystalline deposits during the long-term follow-up of <TextGroup><PlainText>11 years.</PlainText></TextGroup> </Pgraph></TextBlock> <TextBlock linked="yes" name="Case description"> <MainHeadline>Case description</MainHeadline><Pgraph>A 27-year-old female patient presented with a progressive visual impairment in both eyes in 2006. She had received charged particle radiation in 1998 for nasopharyngeal carcinoma together with 3 cycles of chemotherapy (each epirubicin 150 mg + cisplatin 150 mg). There was no history of diabetes mellitus, arterial hypertension or any other systemic vascular diseases. </Pgraph><Pgraph>At the initial presentation, the best-corrected visual acuity was 20/100 in the right eye and 20/50 in the left eye (bilateral –3.00 spherical equivalent). The intraocular pressure and slit lamp examination of the anterior segment was unremarkable. Funduscopic examination of the right eye revealed intraretinal hemorrhages, exudates, and a diffuse macular edema. The left retina showed modest intraretinal hemorrhages and microaneurisms at the posterior pole and enlarged arterial calibration (Figure 1 A, B <ImgLink imgNo="1" imgType="figure"/>). Fundus fluorescein angiography (FFA) <TextGroup><PlainText>revealed</PlainText></TextGroup> an enlarged and clear-cut foveal avascular zone with perifoveal telangiectasia, which was more <TextGroup><PlainText>pr</PlainText></TextGroup>on<TextGroup><PlainText>ounced</PlainText></TextGroup> in the right eye. Diffuse macular leakage was observed in the late venous phase bilaterally (Figure 1 C, D <ImgLink imgNo="1" imgType="figure"/>). </Pgraph><Pgraph>The ischemic macular changes and medical history of radiation therapy suggested us the diagnosis of radiation maculopathy. The patient was subsequently treated with one session focal laser photocoagulation OU and multiple intravitreal injections in between 2006 and 2014 <TextGroup><PlainText>(5 Bevacizumab</PlainText></TextGroup>, 1 Pegaptanib and 6 Ranibizumab <TextGroup><PlainText>injections</PlainText></TextGroup> for OD and 1 Bevacizumab, 2 Pegaptanib, and 2 Ranibizumab injections for OS). Consequently, the macular edema resolved, the visual acuity improved to 20/40 right and 20/30 left, and the patient was followed in longer periodic intervals. During a routine examination in 2013, we noticed retinal crystals, which <TextGroup><PlainText>surrounded</PlainText></TextGroup> and spared the fovea (Figure 2 A, B <ImgLink imgNo="2" imgType="figure"/>). Optical coherence tomography (OCT) showed hyperreflective dots mainly located in the superficial nerve fibre layer, which <TextGroup><PlainText>corr</PlainText></TextGroup>es<TextGroup><PlainText>ponded</PlainText></TextGroup> to the crystalline deposits and additionally punctate hyperreflectivity in the outer plexiform and nuclear layer (Figure 2 C, D <ImgLink imgNo="2" imgType="figure"/>). However, as the old fundus camera was replaced in 2013 all color pictures could not be reviewed. Only the first colour picture captured at the presentation had copies. </Pgraph><Pgraph>In between 2014 and 2017, functional and morphological findings were stable without necessitating further <TextGroup><PlainText>treatment</PlainText></TextGroup>. However, the crystalline deposits changed throughout slightly. </Pgraph></TextBlock> <TextBlock linked="yes" name="Discussion"> <MainHeadline>Discussion</MainHeadline><Pgraph>Radiation-induced vision loss remains an important challenge in the treatment of ocular oncology. Especially in patients with choroidal melanoma receiving scleral plaque radiotherapy, RM can occur in up to 46% <TextLink reference="4"></TextLink>. Therapeutic apical radiation doses in excess of tissue tolerance induce a progressive change in capillary architecture, which contribute to the development and the maintenance of macular edema <TextLink reference="1"></TextLink>, <TextLink reference="2"></TextLink>, <TextLink reference="5"></TextLink>, <TextLink reference="6"></TextLink>. Continuous and periodic VEGF inhibitors or intravitreal steroids can be used for preventing vision loss and scarring <TextLink reference="7"></TextLink>. </Pgraph><Pgraph>The clinical course of our case corresponds to a typical RM. The patient noticed visual deterioration seven years after the head radiation. During the follow-up, we observed frequent relapses of macular edema. Common intravitreal anti-VEGF injections were needed to achieve a functionally and morphologically stable retina.</Pgraph><Pgraph>The current case distinguishes itself by retinal tiny crystalline deposits in both eyes, which were observed 7 years after the initial presentation. Interestingly, these crystals showed no autofluorescence and were hyperreflective in infrared scanning laser ophthalmoscopy (SLO) images (Figure 3 <ImgLink imgNo="3" imgType="figure"/>). Optical coherence tomography revealed a corresponding hyperreflectivity in superficial layers. In the further clinical course these crystals have almost not changed in amount and morphology.</Pgraph><Pgraph>Several clinical entities can contribute to the presence of crystalline deposits in the retina <TextLink reference="8"></TextLink>. In our case, we found no laboratory evidence for metabolic disorders or electrolyte imbalances. Specific drug ingestion, like tamoxifen, canthaxanthine, ritonavir or nitrofurantoin, was denied. </Pgraph><Pgraph>Our patient was previously treated with cisplatin, which has well-known adverse effects such as nephro- and neurotoxicity, especially with intraarterial application <TextLink reference="9"></TextLink>, <TextLink reference="10"></TextLink>. In a recent case-controlled study by Dulz et al. <TextLink reference="11"></TextLink>, OCT and ERG parameters were analysed in 28 eyes of 14 patients, who were treated with cisplatin. They found a significant correlation between the cumulative cisplatin dose and retinal nerve fiber layer (RNFL) thinning. No significant differences were observed in visual acuity, colour vision or ERG amplitudes, in comparison to controls. Morphological retinal changes like crystalline <TextGroup><PlainText>deposits</PlainText></TextGroup> were not reported in this work.</Pgraph><Pgraph>Retinal crystals can be seen in macular teleangiectasia (MacTel), too, which is an acquired bilateral macular disorder, with a primarily neurodegenerative <TextGroup><PlainText>pathogen</PlainText></TextGroup>esis. It is characterized by minimal dilatation of the parafoveal capillaries, graying of the central maculae and also crystalline deposits in superficial layers. Sallo et al. <TextLink reference="12"></TextLink>, analyzed the data derived from the MacTel study and reported crystalline deposits in 46% (203 out of 443) of patients. In a multicentre study by Baumüller et al. <TextLink reference="13"></TextLink>, they analysed the SD-OCT features of 41 patients with mactel type 2. In all eyes SD-OCT revealed distinct hyperreflective spots (HRS) in all retinal layers including the outer retinal layers. Crystalline deposits visualized on fundus photographs, correlated to highly reflective spots in the superficial retina. The authors suggest that these HRS and bands are the results of a nonspecific neurodegenerative process. </Pgraph><Pgraph>Especially in RM, Frizziero et al. <TextLink reference="14"></TextLink> analysed the presence of HRS with SD-OCT. They found them preferentially in the outer plexiform and outer nuclear layer, in all of <TextGroup><PlainText>25 affected</PlainText></TextGroup> eyes with RM. These HRSs significantly increased in number, according to OCT central subfield thickness. The authors considered HRSs as a biomarker for RM activity, and assessed them mainly as a sign of retinal inflammation. Funduscopic images were not correlated and specific crystals were not reported. </Pgraph><Pgraph>The precise nature and molecular constituents of the retinal crystals in our case will remain unclear. Various possibilities can be considered, but in view of the morphological similarities with macular telangiectasia we want to suggest a possible neurodegenerative process in the pathogenesis of radiation maculopathy. </Pgraph></TextBlock> <TextBlock linked="yes" name="Notes"> <MainHeadline>Notes</MainHeadline><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph></TextBlock> <References linked="yes"> <Reference refNo="1"> <RefAuthor>Archer DB</RefAuthor> <RefAuthor>Amoaku WM</RefAuthor> <RefAuthor>Gardiner TA</RefAuthor> <RefTitle>Radiation retinopathy--clinical, histopathological, ultrastructural and experimental correlations</RefTitle> <RefYear>1991</RefYear> <RefJournal>Eye (Lond)</RefJournal> <RefPage>239-51</RefPage> <RefTotal>Archer DB, Amoaku WM, Gardiner TA. Radiation retinopathy--clinical, histopathological, ultrastructural and experimental correlations. Eye (Lond). 1991;5 ( Pt 2):239-51. DOI: 10.1038/eye.1991.39</RefTotal> <RefLink>http://dx.doi.org/10.1038/eye.1991.39</RefLink> </Reference> <Reference refNo="2"> <RefAuthor>Horgan N</RefAuthor> <RefAuthor>Shields CL</RefAuthor> <RefAuthor>Mashayekhi A</RefAuthor> <RefAuthor>Shields JA</RefAuthor> <RefTitle>Classification and treatment of radiation maculopathy</RefTitle> <RefYear>2010</RefYear> <RefJournal>Curr Opin Ophthalmol</RefJournal> <RefPage>233-8</RefPage> <RefTotal>Horgan N, Shields CL, Mashayekhi A, Shields JA. Classification and treatment of radiation maculopathy. Curr Opin Ophthalmol. 2010 May;21(3):233-8. DOI: 10.1097/ICU.0b013e3283386687</RefTotal> <RefLink>http://dx.doi.org/10.1097/ICU.0b013e3283386687</RefLink> </Reference> <Reference refNo="3"> <RefAuthor>Gündüz K</RefAuthor> <RefAuthor>Shields CL</RefAuthor> <RefAuthor>Shields JA</RefAuthor> <RefAuthor>Cater J</RefAuthor> <RefAuthor>Freire JE</RefAuthor> <RefAuthor>Brady LW</RefAuthor> <RefTitle>Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement</RefTitle> <RefYear>1999</RefYear> <RefJournal>Am J Ophthalmol</RefJournal> <RefPage>579-89</RefPage> <RefTotal>Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol. 1999 May;127(5):579-89. DOI: 10.1016/S0002-9394(98)00445-0</RefTotal> <RefLink>http://dx.doi.org/10.1016/S0002-9394(98)00445-0</RefLink> </Reference> <Reference refNo="4"> <RefAuthor>Guyer DR</RefAuthor> <RefAuthor>Mukai S</RefAuthor> <RefAuthor>Egan KM</RefAuthor> <RefAuthor>Seddon JM</RefAuthor> <RefAuthor>Walsh SM</RefAuthor> <RefAuthor>Gragoudas ES</RefAuthor> <RefTitle>Radiation maculopathy after proton beam irradiation for choroidal melanoma</RefTitle> <RefYear>1992</RefYear> <RefJournal>Ophthalmology</RefJournal> <RefPage>1278-85</RefPage> <RefTotal>Guyer DR, Mukai S, Egan KM, Seddon JM, Walsh SM, Gragoudas ES. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology. 1992 Aug;99(8):1278-85. DOI: 10.1016/S0161-6420(92)31832-9</RefTotal> <RefLink>http://dx.doi.org/10.1016/S0161-6420(92)31832-9</RefLink> </Reference> <Reference refNo="5"> <RefAuthor>American Brachytherapy Society - Ophthalmic Oncology Task Force</RefAuthor> <RefTitle>Electronic address: paulfinger@eyecancer.com; ABS – OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma</RefTitle> <RefYear>2014</RefYear> <RefJournal>Brachytherapy</RefJournal> <RefPage>1-14</RefPage> <RefTotal>American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com; ABS – OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014 Jan-Feb;13(1):1-14. DOI: 10.1016/j.brachy.2013.11.008</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.brachy.2013.11.008</RefLink> </Reference> <Reference refNo="6"> <RefAuthor>Finger PT</RefAuthor> <RefAuthor>Chin KJ</RefAuthor> <RefAuthor>Yu GP</RefAuthor> <RefAuthor> Palladium-103 for Choroidal Melanoma Study Group</RefAuthor> <RefTitle>Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma</RefTitle> <RefYear>2010</RefYear> <RefJournal>Am J Ophthalmol</RefJournal> <RefPage>608-15</RefPage> <RefTotal>Finger PT, Chin KJ, Yu GP; Palladium-103 for Choroidal Melanoma Study Group. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol. 2010 Apr;149(4):608-15. DOI: 10.1016/j.ajo.2009.11.006</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.ajo.2009.11.006</RefLink> </Reference> <Reference refNo="7"> <RefAuthor>Russo A</RefAuthor> <RefAuthor>Reibaldi M</RefAuthor> <RefAuthor>Avitabile T</RefAuthor> <RefAuthor>Uva MG</RefAuthor> <RefAuthor>Franco LM</RefAuthor> <RefAuthor>Gagliano C</RefAuthor> <RefAuthor>Bonfiglio V</RefAuthor> <RefAuthor>Spatola C</RefAuthor> <RefAuthor>Privitera G</RefAuthor> <RefAuthor>Longo A</RefAuthor> <RefTitle>Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma</RefTitle> <RefYear>2018</RefYear> <RefJournal>Retina (Philadelphia, Pa)</RefJournal> <RefPage>788-94</RefPage> <RefTotal>Russo A, Reibaldi M, Avitabile T, Uva MG, Franco LM, Gagliano C, Bonfiglio V, Spatola C, Privitera G, Longo A. Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma. Retina (Philadelphia, Pa). 2018 Apr;38(4):788-94. DOI: 10.1097/IAE.0000000000001585</RefTotal> <RefLink>http://dx.doi.org/10.1097/IAE.0000000000001585</RefLink> </Reference> <Reference refNo="8"> <RefAuthor>Nadim F</RefAuthor> <RefAuthor>Walid H</RefAuthor> <RefAuthor>Adib J</RefAuthor> <RefTitle>The differential diagnosis of crystals in the retina</RefTitle> <RefYear>2001</RefYear> <RefJournal>Int Ophthalmol</RefJournal> <RefPage>113-21</RefPage> <RefTotal>Nadim F, Walid H, Adib J. The differential diagnosis of crystals in the retina. Int Ophthalmol. 2001;24(3):113-21. DOI: 10.1023/A:1021189215498</RefTotal> <RefLink>http://dx.doi.org/10.1023/A:1021189215498</RefLink> </Reference> <Reference refNo="9"> <RefAuthor>Kwan AS</RefAuthor> <RefAuthor>Sahu A</RefAuthor> <RefAuthor>Palexes G</RefAuthor> <RefTitle>Retinal ischemia with neovascularization in cisplatin related retinal toxicity</RefTitle> <RefYear>2006</RefYear> <RefJournal>Am J Ophthalmol</RefJournal> <RefPage>196-7</RefPage> <RefTotal>Kwan AS, Sahu A, Palexes G. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. Am J Ophthalmol. 2006 Jan;141(1):196-7. DOI: 10.1016/j.ajo.2005.07.046</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.ajo.2005.07.046</RefLink> </Reference> <Reference refNo="10"> <RefAuthor>Hilliard LM</RefAuthor> <RefAuthor>Berkow RL</RefAuthor> <RefAuthor>Watterson J</RefAuthor> <RefAuthor>Ballard EA</RefAuthor> <RefAuthor>Balzer GK</RefAuthor> <RefAuthor>Moertel CL</RefAuthor> <RefTitle>Retinal toxicity associated with cisplatin and etoposide in pediatric patients</RefTitle> <RefYear>1997</RefYear> <RefJournal>Med Pediatr Oncol</RefJournal> <RefPage>310-3</RefPage> <RefTotal>Hilliard LM, Berkow RL, Watterson J, Ballard EA, Balzer GK, Moertel CL. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol. 1997 Apr;28(4):310-3.</RefTotal> </Reference> <Reference refNo="11"> <RefAuthor>Dulz S</RefAuthor> <RefAuthor>Asselborn NH</RefAuthor> <RefAuthor>Dieckmann KP</RefAuthor> <RefAuthor>Matthies C</RefAuthor> <RefAuthor>Wagner W</RefAuthor> <RefAuthor>Weidmann J</RefAuthor> <RefAuthor>Seidel C</RefAuthor> <RefAuthor>Oing C</RefAuthor> <RefAuthor>Berger LA</RefAuthor> <RefAuthor>Alsdorf W</RefAuthor> <RefAuthor>Mankichian B</RefAuthor> <RefAuthor>Meyer C</RefAuthor> <RefAuthor>Vetterlein MW</RefAuthor> <RefAuthor>Gild P</RefAuthor> <RefAuthor>Ludwig TA</RefAuthor> <RefAuthor>Soave A</RefAuthor> <RefAuthor>Schriefer P</RefAuthor> <RefAuthor>Becker A</RefAuthor> <RefAuthor>Ahyai SA</RefAuthor> <RefAuthor>Oechsle K</RefAuthor> <RefAuthor>Bokemeyer C</RefAuthor> <RefAuthor>Wagenfeld L</RefAuthor> <RefAuthor>Fisch M</RefAuthor> <RefAuthor>Hartmann M</RefAuthor> <RefAuthor>Chun FK</RefAuthor> <RefAuthor>Kluth LA</RefAuthor> <RefTitle>Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer</RefTitle> <RefYear>2017</RefYear> <RefJournal>J Cancer Res Clin Oncol</RefJournal> <RefPage>1319-25</RefPage> <RefTotal>Dulz S, Asselborn NH, Dieckmann KP, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger LA, Alsdorf W, Mankichian B, Meyer C, Vetterlein MW, Gild P, Ludwig TA, Soave A, Schriefer P, Becker A, Ahyai SA, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun FK, Kluth LA. Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. J Cancer Res Clin Oncol. 2017 Jul;143(7):1319-25. DOI: 10.1007/s00432-017-2384-8</RefTotal> <RefLink>http://dx.doi.org/10.1007/s00432-017-2384-8</RefLink> </Reference> <Reference refNo="12"> <RefAuthor>Sallo FB</RefAuthor> <RefAuthor>Leung I</RefAuthor> <RefAuthor>Chung M</RefAuthor> <RefAuthor>Wolf-Schnurrbusch UE</RefAuthor> <RefAuthor>Dubra A</RefAuthor> <RefAuthor>Williams DR</RefAuthor> <RefAuthor>Clemons T</RefAuthor> <RefAuthor>Pauleikhoff D</RefAuthor> <RefAuthor>Bird AC</RefAuthor> <RefAuthor>Peto T</RefAuthor> <RefAuthor> MacTel Study Group</RefAuthor> <RefTitle>Retinal crystals in type 2 idiopathic macular telangiectasia</RefTitle> <RefYear>2011</RefYear> <RefJournal>Ophthalmology</RefJournal> <RefPage>2461-7</RefPage> <RefTotal>Sallo FB, Leung I, Chung M, Wolf-Schnurrbusch UE, Dubra A, Williams DR, Clemons T, Pauleikhoff D, Bird AC, Peto T; MacTel Study Group. Retinal crystals in type 2 idiopathic macular telangiectasia. Ophthalmology. 2011 Dec;118(12):2461-7. DOI: 10.1016/j.ophtha.2011.05.022</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.ophtha.2011.05.022</RefLink> </Reference> <Reference refNo="13"> <RefAuthor>Baumüller S</RefAuthor> <RefAuthor>Charbel Issa P</RefAuthor> <RefAuthor>Scholl HP</RefAuthor> <RefAuthor>Schmitz-Valckenberg S</RefAuthor> <RefAuthor>Holz FG</RefAuthor> <RefTitle>Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2</RefTitle> <RefYear>2010</RefYear> <RefJournal>Ophthalmology</RefJournal> <RefPage>2162-8</RefPage> <RefTotal>Baumüller S, Charbel Issa P, Scholl HP, Schmitz-Valckenberg S, Holz FG. Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2. Ophthalmology. 2010 Nov;117(11):2162-8. DOI: 10.1016/j.ophtha.2010.02.014</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.ophtha.2010.02.014</RefLink> </Reference> <Reference refNo="14"> <RefAuthor>Frizziero L</RefAuthor> <RefAuthor>Parrozzani R</RefAuthor> <RefAuthor>Midena G</RefAuthor> <RefAuthor>Miglionico G</RefAuthor> <RefAuthor>Vujosevic S</RefAuthor> <RefAuthor>Pilotto E</RefAuthor> <RefAuthor>Midena E</RefAuthor> <RefTitle>Hyperreflective intraretinal spots in radiation macular edema on spectral domain optical coherence tomography</RefTitle> <RefYear>2016</RefYear> <RefJournal>Retina (Philadelphia, Pa)</RefJournal> <RefPage>1664-9</RefPage> <RefTotal>Frizziero L, Parrozzani R, Midena G, Miglionico G, Vujosevic S, Pilotto E, Midena E. Hyperreflective intraretinal spots in radiation macular edema on spectral domain optical coherence tomography. Retina (Philadelphia, Pa). 2016 Sep;36(9):1664-9. DOI: 10.1097/IAE.0000000000000986</RefTotal> <RefLink>http://dx.doi.org/10.1097/IAE.0000000000000986</RefLink> </Reference> </References> <Media> <Tables> <NoOfTables>0</NoOfTables> </Tables> <Figures> <Figure format="png" height="661" width="827"> <MediaNo>1</MediaNo> <MediaID>1</MediaID> <Caption><Pgraph><Mark1>Figure 1: Color fundus photography (initial manifestation): radiation maculopathy with enlarged arterial calibration, intraretinal hemorrhages, exudates, microaneurisms, and diffuse macular edema (A, B)</Mark1></Pgraph><Pgraph><Mark1>Fundus fluorescein angiography (late venous phase): bilateral enlarged and clear-cut foveal avascular zone with perifoveal teleangiectasia and diffuse macular edema (C, D)</Mark1></Pgraph></Caption> </Figure> <Figure format="png" height="604" width="827"> <MediaNo>2</MediaNo> <MediaID>2</MediaID> <Caption><Pgraph><Mark1>Figure 2: Color fundus photography (Eleven years after initial presentation): retinal crystals surrounding the fovea bilaterally (A, B). Optical coherence tomography (single horizontal linear scan): punctate hyperreflectivity in near all retinal layers. Retinal crystals are corresponding to superficial hyperreflective spots (C, D). </Mark1></Pgraph></Caption> </Figure> <Figure format="png" height="869" width="886"> <MediaNo>3</MediaNo> <MediaID>3</MediaID> <Caption><Pgraph><Mark1>Figure 3: Infrared scanning laser ophthalmoscopy images: punctate hyperreflectivity </Mark1><Mark1>(A, B). Fundus autofluorescense: hypoautofluorescence due to old laser scars (C, D).</Mark1></Pgraph></Caption> </Figure> <NoOfPictures>3</NoOfPictures> </Figures> <InlineFigures> <NoOfPictures>0</NoOfPictures> </InlineFigures> <Attachments> <NoOfAttachments>0</NoOfAttachments> </Attachments> </Media> </OrigData> </GmsArticle>